210 related articles for article (PubMed ID: 21829963)
1. Impact of the National Health Fund policy on hormone treatment for prostate cancer in Jamaica.
Morrison BF; Aiken WD; Reid ME
Rev Panam Salud Publica; 2011 Jun; 29(6):404-8. PubMed ID: 21829963
[TBL] [Abstract][Full Text] [Related]
2. The cost value of medical versus surgical hormonal therapy for metastatic prostate cancer.
Chon JK; Jacobs SC; Naslund MJ
J Urol; 2000 Sep; 164(3 Pt 1):735-7. PubMed ID: 10953136
[TBL] [Abstract][Full Text] [Related]
3. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
4. Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer.
Garje R; Chennamadhavuni A; Mott SL; Chambers IM; Gellhaus P; Zakharia Y; Brown JA
Clin Genitourin Cancer; 2020 Apr; 18(2):e157-e166. PubMed ID: 31956009
[TBL] [Abstract][Full Text] [Related]
5. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
6. Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study.
Mariani AJ; Glover M; Arita S
J Urol; 2001 Jan; 165(1):104-7. PubMed ID: 11125375
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
Bayoumi AM; Brown AD; Garber AM
J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.
Lapi F; Azoulay L; Niazi MT; Yin H; Benayoun S; Suissa S
JAMA; 2013 Jul; 310(3):289-96. PubMed ID: 23860987
[TBL] [Abstract][Full Text] [Related]
9. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
10. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
Gandaglia G; Sun M; Hu JC; Novara G; Choueiri TK; Nguyen PL; Schiffmann J; Graefen M; Shariat SF; Abdollah F; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI
Eur Urol; 2014 Dec; 66(6):1125-32. PubMed ID: 24495466
[TBL] [Abstract][Full Text] [Related]
11. Monotherapy in advanced prostate cancer: an overview.
Baltogiannis D; Giannakopoulos X; Charalabopoulos K; Sofikitis N
Exp Oncol; 2004 Sep; 26(3):185-91. PubMed ID: 15494685
[TBL] [Abstract][Full Text] [Related]
12. Hormonal therapy for stage D cancer of the prostate.
Gudziak MR; Smith AY
West J Med; 1994 Apr; 160(4):351-9. PubMed ID: 8023485
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?
Krahn M; Bremner KE; Tomlinson G; Luo J; Ritvo P; Naglie G; Alibhai SM
BJU Int; 2011 Nov; 108(10):1588-96. PubMed ID: 21453344
[TBL] [Abstract][Full Text] [Related]
14. [Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer].
Fujikawa K; Awakura Y; Okabe T; Watanabe R; Nishimura S
Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):503-11; discussion 511-2. PubMed ID: 12795165
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
Sun M; Choueiri TK; Hamnvik OP; Preston MA; De Velasco G; Jiang W; Loeb S; Nguyen PL; Trinh QD
JAMA Oncol; 2016 Apr; 2(4):500-7. PubMed ID: 26720632
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.
Hoda MR; Kramer MW; Merseburger AS; Cronauer MV
Expert Opin Pharmacother; 2017 Jan; 18(1):105-113. PubMed ID: 27826989
[TBL] [Abstract][Full Text] [Related]
17. Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study.
Chen DY; See LC; Liu JR; Chuang CK; Pang ST; Hsieh IC; Wen MS; Chen TH; Lin YC; Liaw CC; Hsu CL; Chang JW; Kuo CF; Huang WK
J Clin Oncol; 2017 Nov; 35(32):3697-3705. PubMed ID: 28968166
[TBL] [Abstract][Full Text] [Related]
18. Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model.
Hong JH; Huang CY; Chang CH; Muo CH; Jaw FS; Lu YC; Chung CJ
Cancer Epidemiol; 2020 Feb; 64():101657. PubMed ID: 31918180
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
Kittai AS; Blank J; Graff JN
Oncology (Williston Park); 2018 Dec; 32(12):599-602, 604-6. PubMed ID: 30632129
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic considerations in the treatment of prostate cancer.
Varenhorst E; Carlsson P; Pedersen K
Pharmacoeconomics; 1994 Aug; 6(2):127-41. PubMed ID: 10147438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
